IL23A and neoplasm: However, despite in early-stage human CRC, elevated expression of IL-23 [84] and IL-17A [85] is recognized as unfavorable prognostic indicators, elevated expression of IL-17A in advanced CRC appears to be associated with improved outcome [86], suggesting that, at some point, IL-17A may stimulate anti-tumor immunity.